SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-023963
Filing Date
2020-02-21
Accepted
2020-02-21 17:16:05
Documents
6
Period of Report
2020-02-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm208100d2_8k.htm 8-K 26055
2 EXHIBIT 1.1 tm208100d2_ex1-1.htm EX-1.1 293222
3 EXHIBIT 4.1 tm208100d2_ex4-1.htm EX-4.1 71044
4 EXHIBIT 5.1 tm208100d2_ex5-1.htm EX-5.1 16106
5 EXHIBIT 5.2 tm208100d2_ex5-2.htm EX-5.2 13616
6 GRAPHIC tm208100d2_ex5-2img01.jpg GRAPHIC 12450
  Complete submission text file 0001104659-20-023963.txt   438743
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 20641162
SIC: 2834 Pharmaceutical Preparations